[go: up one dir, main page]

WO2010027498A3 - Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions - Google Patents

Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions Download PDF

Info

Publication number
WO2010027498A3
WO2010027498A3 PCT/US2009/005016 US2009005016W WO2010027498A3 WO 2010027498 A3 WO2010027498 A3 WO 2010027498A3 US 2009005016 W US2009005016 W US 2009005016W WO 2010027498 A3 WO2010027498 A3 WO 2010027498A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
provides
dosage form
ileum
dependent diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/005016
Other languages
French (fr)
Other versions
WO2010027498A2 (en
Inventor
Joseph M. Fayad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEW SCIENCE HOLDINGS LLC
Original Assignee
NEW SCIENCE HOLDINGS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEW SCIENCE HOLDINGS LLC filed Critical NEW SCIENCE HOLDINGS LLC
Publication of WO2010027498A2 publication Critical patent/WO2010027498A2/en
Publication of WO2010027498A3 publication Critical patent/WO2010027498A3/en
Priority to US12/932,633 priority Critical patent/US9757346B2/en
Anticipated expiration legal-status Critical
Priority to US15/623,734 priority patent/US20180369177A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty- four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum. The present invention also provides a method for treating noninsulin dependent diabetes mellitus, pre-diabetic symptoms, and insulin resistance, as well as a number of disease states and conditions including gastrointestinal disorders as otherwise described herein.
PCT/US2009/005016 2008-09-03 2009-09-02 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions Ceased WO2010027498A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/932,633 US9757346B2 (en) 2008-09-03 2011-03-02 Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
US15/623,734 US20180369177A1 (en) 2008-09-03 2017-06-15 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19081808P 2008-09-03 2008-09-03
US61/190,818 2008-09-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/932,633 Continuation-In-Part US9757346B2 (en) 2008-09-03 2011-03-02 Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)

Publications (2)

Publication Number Publication Date
WO2010027498A2 WO2010027498A2 (en) 2010-03-11
WO2010027498A3 true WO2010027498A3 (en) 2010-06-03

Family

ID=41797725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/005016 Ceased WO2010027498A2 (en) 2008-09-03 2009-09-02 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions

Country Status (1)

Country Link
WO (1) WO2010027498A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8999721B2 (en) 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US20190262367A1 (en) * 2010-03-03 2019-08-29 Volant Holdings Gmbh Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes
EP2407034A1 (en) * 2010-07-17 2012-01-18 Cognis IP Management GmbH Particles
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
EP2680859B1 (en) 2011-03-02 2022-04-27 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
AU2014236559B2 (en) 2013-03-14 2020-03-12 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
JP6464142B2 (en) 2013-03-14 2019-02-06 セラバイオーム，エルエルシー Targeted gastrointestinal delivery of probiotic organisms and / or therapeutic agents
CN112074197A (en) * 2018-03-07 2020-12-11 安纳生物科技有限公司 Compositions for type II diabetes and for providing sustained energy release over time
WO2020120519A1 (en) 2018-12-10 2020-06-18 Aphaia Pharma Ag Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines
HUE057346T2 (en) 2018-12-10 2022-05-28 Aphaia Ip Ag Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines
CA3182019A1 (en) 2020-06-10 2021-12-16 Steffen-Sebastian Bolz Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents
WO2025119939A1 (en) 2023-12-03 2025-06-12 Aphaia Pharma Ag Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions
LU103233B1 (en) 2023-12-21 2025-06-24 Aphaia Ip Ag Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322697A (en) * 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US20050244518A1 (en) * 2000-06-12 2005-11-03 Ruo Huang Dietary supplement and related method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322697A (en) * 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US20050244518A1 (en) * 2000-06-12 2005-11-03 Ruo Huang Dietary supplement and related method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MELA, D. J.: "Novel food technologies: enhancing appetite control in liquid meal replacers", OBESITY, vol. 14, no. SUPP., July 2006 (2006-07-01), pages 179S - 181S *

Also Published As

Publication number Publication date
WO2010027498A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2010027498A3 (en) Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
WO2011094337A8 (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CL2007003440A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISEASES SUCH AS TYPE 2 DIABETES, INSULIN RESISTANCE, LIPID DISORDERS, OBESIDA
CO6270215A2 (en) TRANS-CLOMPHENE FOR METABOLIC SYNDROME
WO2008030830A3 (en) Sustained-release composition and method of use thereof
UA98962C2 (en) Thyroid hormone analogues, pharmaceutical composition comprising thereof, method for the treatment using thereof, use thereof and preparation method
WO2005039546A3 (en) Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
WO2008027687A3 (en) Use of tenecteplase for treating acute ischemic stroke
WO2007081975A3 (en) Method of treating multiple sclerosis
WO2007122635A3 (en) Controlled release formulation comprising anti-epileptic drugs
BR0314619A (en) Ghrh's analogs
NZ600094A (en) Method of enhancing muscle protein synthesis
EA201100565A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF INTESTINAL DISEASES USING GRANULATED MESALAMINE
JP2021193118A (en) Composition and method for treatment of neuropsychiatric disorders
RS60556B1 (en) Fused benzazepines for treatment of stuttering
WO2010051196A8 (en) Novel substituted azabenzoxazoles
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
CN104884052A (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
RU2009144121A (en) COMPOSITIONS (-) - E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
JP2016538269A (en) Methods for the treatment of muscular dystrophy
Mizrahi et al. Side effects profile in humans of 11C-(+)-PHNO, a dopamine D2/3 agonist ligand for PET
EP2530087A3 (en) Sequences of brachyspira, immunogenic composition, methods for preparation and use thereof
CN102802630A (en) Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
Müller et al. Entacapone improves complex movement performance in patients with Parkinson’s disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09811852

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 17.05.11 AND 02.08.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09811852

Country of ref document: EP

Kind code of ref document: A2